BR0314539A - Associação entre um ligante dos ppar e um agente antioxidante e utilização no tratamento da obesidade - Google Patents

Associação entre um ligante dos ppar e um agente antioxidante e utilização no tratamento da obesidade

Info

Publication number
BR0314539A
BR0314539A BR0314539-5A BR0314539A BR0314539A BR 0314539 A BR0314539 A BR 0314539A BR 0314539 A BR0314539 A BR 0314539A BR 0314539 A BR0314539 A BR 0314539A
Authority
BR
Brazil
Prior art keywords
association
ppar
antioxidant
binder
obesity treatment
Prior art date
Application number
BR0314539-5A
Other languages
English (en)
Inventor
Louis Casteilla
Luc Penicaud
Catherine Dacquet
Pierre Renard
Original Assignee
Servier Lab
Centre Nat Rech Scient
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab, Centre Nat Rech Scient filed Critical Servier Lab
Publication of BR0314539A publication Critical patent/BR0314539A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

"ASSOCIAçãO ENTRE UM LIGANTE DOS PPAR E UM AGENTE ANTIOXIDANTE E UTILIZAçãO NO TRATAMENTO DA OBESIDADE". A presente invenção refere-se a uma associação que contém um ou vários ligantes dos receptores ativados pelos proliferadores de peroxisomas e um agente antioxidante. Medicamentos.
BR0314539-5A 2002-10-11 2003-10-10 Associação entre um ligante dos ppar e um agente antioxidante e utilização no tratamento da obesidade BR0314539A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0212646A FR2845602B1 (fr) 2002-10-11 2002-10-11 Association entre un ligand des recepteurs actives par les proliferateurs de peroxisomes et un agent antioxydant et les compositions pharmaceutiques qui les contiennent
PCT/FR2003/002986 WO2004032967A1 (fr) 2002-10-11 2003-10-10 Association entre un ligand des ppar et un agent antioxydant et utilisation dans le traitement de l'obesite

Publications (1)

Publication Number Publication Date
BR0314539A true BR0314539A (pt) 2005-07-26

Family

ID=32039639

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0314539-5A BR0314539A (pt) 2002-10-11 2003-10-10 Associação entre um ligante dos ppar e um agente antioxidante e utilização no tratamento da obesidade

Country Status (20)

Country Link
US (1) US20060002911A1 (pt)
EP (2) EP1815858A3 (pt)
JP (1) JP2006505548A (pt)
KR (1) KR20050072759A (pt)
CN (1) CN100571776C (pt)
AR (1) AR041579A1 (pt)
AU (1) AU2003299772C1 (pt)
BR (1) BR0314539A (pt)
CA (1) CA2501964A1 (pt)
EA (1) EA010353B1 (pt)
FR (1) FR2845602B1 (pt)
GE (1) GEP20084462B (pt)
MA (1) MA27402A1 (pt)
MX (1) MXPA05003893A (pt)
MY (1) MY140562A (pt)
NO (1) NO20052231L (pt)
NZ (2) NZ566708A (pt)
PL (1) PL376045A1 (pt)
UA (1) UA81132C2 (pt)
WO (1) WO2004032967A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090202659A1 (en) * 2005-06-10 2009-08-13 Gimble Jeffrey M Modulation of Peripheral Clocks in Adipose Tissue
JP4863204B2 (ja) * 2005-06-15 2012-01-25 独立行政法人産業技術総合研究所 腎症関連疾患の診断方法及び診断キット
AU2007299920A1 (en) * 2006-09-19 2008-03-27 Braincells, Inc. PPAR Mediated Modulation of Neurogenesis
US20100022442A1 (en) * 2008-07-25 2010-01-28 Ambryx Biotechnology, Inc. Compositions and methods for increasing serum antioxidant concentrations, decreasing serum triglyceride levels, inhibiting insulin-receptor signaling activity, increasing serum ghrelin levels, and decreasing serum tnf-alpha levels
AU2010247800A1 (en) 2009-05-11 2011-12-15 Berg Llc Methods for the diagnosis of metabolic disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencers
CA2832324C (en) 2011-04-04 2022-03-15 Berg Llc Methods of treating central nervous system tumors
SG10201903112WA (en) 2013-04-08 2019-05-30 Berg Llc Treatment of cancer using coenzyme q10 combination therapies
KR102370843B1 (ko) 2013-09-04 2022-03-04 버그 엘엘씨 코엔자임 q10의 연속주입에 의한 암치료 방법
CN107005018B (zh) * 2014-10-02 2019-09-20 瑞士苏黎世联邦理工学院 脉冲激光器
WO2017087576A1 (en) 2015-11-16 2017-05-26 Berg Llc Methods of treatment of temozolomide-resistant glioma using coenzyme q10

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2730231B1 (fr) * 1995-02-02 1997-04-04 Fournier Sca Lab Association de fenofibrate et de vitamine e, utilisation en therapeutique
US5847008A (en) * 1996-02-02 1998-12-08 Merck & Co., Inc. Method of treating diabetes and related disease states
AU1856997A (en) * 1996-02-02 1997-08-22 Merck & Co., Inc. Method for raising hdl cholesterol levels
GB0019226D0 (en) * 2000-08-04 2000-09-27 Smithkline Beecham Plc Novel pharmaceutical
DE10044805A1 (de) * 2000-09-11 2002-04-04 Martin Klingenberg Verwendung von Coenzym Q zur Regulierung der Funktion der Entkopplerproteine
MXPA03003733A (es) * 2000-10-26 2004-10-15 Fournier Lab Ireland Ltd Combinacion de fenofibrato y coenzima q10 para el tratamiento de la disfuncion endotelial.
WO2002060388A2 (en) * 2001-01-30 2002-08-08 Merck & Co., Inc. Acyl sulfamides for treatment of obesity, diabetes and lipid disorders
AU2002251978B2 (en) * 2001-02-09 2007-07-19 Merck & Co., Inc. 2-aryloxy-2-arylalkanoic acids for diabetes and lipid disorders
WO2002064130A1 (en) * 2001-02-15 2002-08-22 Pfizer Products Inc. Proliferative activator receptor (ppar) compounds
EP1360172A1 (en) * 2001-02-15 2003-11-12 Pfizer Products Inc. Ppar agonists

Also Published As

Publication number Publication date
JP2006505548A (ja) 2006-02-16
EA010353B1 (ru) 2008-08-29
MY140562A (en) 2009-12-31
NZ566708A (en) 2009-11-27
NZ539331A (en) 2008-08-29
CN100571776C (zh) 2009-12-23
GEP20084462B (en) 2008-08-25
EP1815858A2 (fr) 2007-08-08
NO20052231L (no) 2005-05-06
UA81132C2 (en) 2007-12-10
EA200500609A1 (ru) 2005-10-27
MA27402A1 (fr) 2005-06-01
EP1549348A1 (fr) 2005-07-06
CA2501964A1 (fr) 2004-04-22
AU2003299772C1 (en) 2009-08-27
MXPA05003893A (es) 2005-08-03
WO2004032967A1 (fr) 2004-04-22
CN1703244A (zh) 2005-11-30
AU2003299772B2 (en) 2009-03-12
AU2003299772A1 (en) 2004-05-04
AR041579A1 (es) 2005-05-18
EP1815858A3 (fr) 2007-12-19
US20060002911A1 (en) 2006-01-05
FR2845602B1 (fr) 2005-07-08
WO2004032967A8 (fr) 2005-05-06
PL376045A1 (en) 2005-12-12
KR20050072759A (ko) 2005-07-12
FR2845602A1 (fr) 2004-04-16

Similar Documents

Publication Publication Date Title
MD960330A (ro) Compuşi nepeptidilici, compoziţie farmaceutică pe baza acestora, metodă de tratament
KR920019342A (ko) 골질환 치료제
CY1110408T1 (el) Συνθεση δισκιου πραμιπεξολης παρατεταμενης απελευθερωσεως
ES2156982T3 (es) Fluidos lubricantes para reducir la oclusion de aire y para la proteccion mejorada del engranaje.
CL2004001174A1 (es) Composicion farmaceutica que comprende: 1-(4-fluorofenil)-3(r)-[3-(4-fluorofenil)-3(s)-hidroxipropil]-4(s)-(4-hidroxifenil)-2-acetidinona (ezetimiba) y excipientes; y su uso en el tratamiento y/o prevencion de aterosclerosis, hipercolesterolemia, dia
EP1631269A4 (en) METHOD AND COMPOSITIONS FOR DISTRIBUTING CATECHOLIC BUTANESE FOR THE TREATMENT OF ADIPOSITAS
BR0008379A (pt) Epotilonas modificadas em c-21
ES2174465T3 (es) Compuestos triazol y su utilizacion como ligandos de dopamina-d.
PT1280541E (pt) Utilizacao de estirpes acetogenicas hidrogenotroficas para a prevencao ou o tratamento de disturbios digestivos
EP1549336A4 (en) PREVENTING AND / OR TREATING INFLAMMATORY ENTERIC DISEASE USING YY PEPTIDES OR PEPTIDE YY ANTAGONISTS
BR0210139A (pt) Composições farmacêuticas
BR0015992A (pt) Compostos, utilização dos mesmos, e, associações terapêuticas
BR0314539A (pt) Associação entre um ligante dos ppar e um agente antioxidante e utilização no tratamento da obesidade
CY1114133T1 (el) ΥΠΟΚΑΤΕΣΤΗΜΕΝΕΣ γ-ΦΑΙΝΥΛ-Δ-ΛΑΚΤΑΜΕΣ ΚΑΙ ΧΡΗΣΕΙΣ ΠΟΥ ΣΧΕΤΙΖΟΝΤΑΙ ΠΡΟΣ ΑΥΤΕΣ
AR056754A1 (es) Composiciones para el tratamiento del cabello
TR200001040T2 (tr) Kaşıntıyı önleme etkisi için bileşiklerin yeni bir kullanımı
GEP20063869B (en) Novel cyclohexyl sulphones
BR0113165A (pt) Derivados de 4-pirimidinamina, composições farmacêuticas e métodos relacionados
CL2004001421A1 (es) Composicion farmaceutica que comprende un compuesto derivado de 1,4-dipiperidin-4-il-piperazina; y su uso para la prevencion y/o tratamiento del dolor.
HUP0001104A2 (hu) Ibuprofent és domperidont tartalmazó készítmények migrén kezelésére
BR0107960A (pt) Tratamento de condições alérgicas e inflamatórias
KR940008674A (ko) 경구용 약제
BR0212989A (pt) Métodos para tratamento neuroprotetor usando inibidores de inos seletivos
YU39598A (sh) Upotreba duloksetina i njegova farmaceutska smeša
DZ2564A1 (fr) Compositions pharmaceutiques pour le traitement dudiabète sucre et d'états associés.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012.